Revenio: Only minor blemishes
Revenio's operating profit in Q4 was broadly in line with our expectations, although the company missed our expectations in bottom rows. The guidance was in line with our expectations and in the big picture, the core business is roaring ahead while future growth drivers (such as HOME2, ILLUME and Oculo) are slowly maturing. Therefore, it’s easy to predict strong value creation for the company well into the future, but this is also reflected in the high valuation (2023e adj. EV/EBIT 28x).
Revenio Group
Revenio is a medical technology company. Within the Group, there is research and development of pressure measurement technology that is used in the treatment of a number of diseases such as glaucoma, osteoporosis, skin cancer, and asthma. Operations are held worldwide and are run via most subsidiaries, each with a business focus. The company's head office is located in Vantaa.
Read more on company pageKey Estimate Figures10.02.2023
2022 | 23e | 24e | |
---|---|---|---|
Revenue | 97.0 | 111.4 | 129.8 |
growth-% | 23.10 % | 14.82 % | 16.56 % |
EBIT (adj.) | 30.9 | 33.9 | 39.7 |
EBIT-% (adj.) | 31.84 % | 30.46 % | 30.56 % |
EPS (adj.) | 0.86 | 0.98 | 1.15 |
Dividend | 0.36 | 0.42 | 0.56 |
Dividend % | 0.93 % | 1.60 % | 2.10 % |
P/E (adj.) | 44.64 | 26.92 | 22.90 |
EV/EBITDA | 30.64 | 18.51 | 15.47 |